Merck & Co., Inc. (NYSE:MRK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Merck & Co., Inc. (NYSE:MRK) has earned an average recommendation of “Moderate Buy” from the twenty-two ratings firms that are presently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $135.50.

A number of equities analysts have recently commented on MRK shares. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target for the company. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Finally, Wells Fargo & Company upped their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Merck & Co., Inc. Trading Down 0.0%

MRK opened at $135.78 on Monday. The firm has a market cap of $334.98 billion, a price-to-earnings ratio of 108.62, a price-to-earnings-growth ratio of 5.86 and a beta of 0.19. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $135.97. The business’s 50 day moving average is $125.54 and its two-hundred day moving average is $120.03. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts predict that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.5%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is 272.00%.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares in the company, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 228,238 shares of company stock worth $29,977,783 over the last three months. 0.17% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

Several large investors have recently modified their holdings of the stock. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $26,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $26,000. Graney & King LLC increased its stake in shares of Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new position in Merck & Co., Inc. during the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.